Caring Brands, Inc. (NASDAQ:CABR) Sees Large Drop in Short Interest

Caring Brands, Inc. (NASDAQ:CABR) was the recipient of a large decline in short interest during the month of July. As of July 31st, there was short interest totaling 427 shares, a decline of 98.8% from the July 15th total of 36,455 shares. Based on an average daily trading volume, of 41,414 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Caring Brands from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 11th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Caring Brands Price Performance

Shares of NASDAQ CABR traded up $0.03 during mid-day trading on Tuesday, reaching $1.47. 34,789 shares of the company’s stock were exchanged, compared to its average volume of 94,620. The stock has a 50-day moving average price of $1.34. The company has a quick ratio of 5.62, a current ratio of 5.66 and a debt-to-equity ratio of 0.03. The firm has a market cap of $13.36 million and a price-to-earnings ratio of -2.30. Caring Brands has a 52 week low of $0.71 and a 52 week high of $5.35.

Caring Brands (NASDAQ:CABR) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.27) earnings per share for the quarter.

Institutional Investors Weigh In On Caring Brands

A hedge fund recently bought a new stake in Caring Brands stock. Jane Street Group LLC purchased a new position in Caring Brands, Inc. (NASDAQ:CABR) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned 0.25% of Caring Brands at the end of the most recent quarter.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.